Day: May 2, 2022
Precision BioSciences to Present Preclinical In Vivo Gene Editing Research at Upcoming American Society of Gene & Cell Therapy 25th Annual Meeting
- Accepted abstracts to be presented as oral presentations and posters highlight preclinical development progress for ARCUS ® gene editing therapies DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS ®
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
Company to Participate in the H.C. Wainwright Global Investment Conference on May 24, 2022 DURHAM, N.C. --(BUSINESS WIRE)--May 2, 2022-- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS®-based ex vivo allogeneic CAR T and in vivo gene editing